Why are Hims & Hers Health shares down 3.7% today?

Traders Union
All News
Stocks
Hims & hers health slides 3.76% today

Highlights

Shareholders of Hims & Hers Health with significant losses may join a class action lawsuit with a November 2, 2026 deadline.
No details on the cause or specifics of the class action lawsuit were provided for Hims & Hers Health investors.
Shares of Hims & Hers Health dropped 3.76% to $29.33, with technicals showing mixed momentum and a forecast range of $27.29 to $31.82 over the next 5 trading days.

Shareholder lawsuit eligibility prompts fresh legal risk exposure

A press release dated September 22, 2026 stated that investors in Hims & Hers Health who have incurred substantial losses may lead a class action lawsuit before the November 2, 2026 deadline. The notice applied specifically to shareholders of Hims & Hers Health Inc. No further details about the lawsuit or its causes were provided in the current information.

Anton Kharitonov, expert at Traders Union, sees heightened risk after the class action news triggered a sharp sell-off in Hims & Hers Health Inc. He emphasizes that strong support at $28.78 could offer temporary relief, but technicals show warning signs, with downside momentum and extreme overbought metrics. The ongoing legal uncertainty, lack of transparency around the lawsuit, and weak directional indicators raise further concern. Current volatility and a bearish MACD reading suggest a fragile setup. "With legal troubles clouding the outlook and technicals flashing caution, I advise traders to avoid chasing bounces and wait for confirmation before any entry."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive view despite the legal headlines. He notes that long-term technical structure is bullish, with price holding above key moving averages and a 67% chance of an upside move in the near term. The market continues to offer setups as price approaches a defined resistance at $30.01 and potential breakout above $31.82. Karapetjanc believes investor sentiment can quickly recover, especially as volatility creates new opportunities. "The bullish structure remains intact and I view pullbacks toward support as attractive buying opportunities for forward-looking investors."

Jainam Mehta, market strategist, takes a scenario-based view given the increased volatility. He highlights the potential for a breakout if resistance at $30.01 is cleared, though the overbought readings warrant tactical caution. Mehta sees opportunity for contrarian entries, with a stop placed just below the $28.78 support. "Traders could play a short-term range but should be ready to pivot quickly if momentum breaks in either direction."

Mixed momentum signals amid overbought conditions and volatility surge

Hims & Hers Health is trading above its 20-day ($28.78) and 200-day ($27.91) moving averages, but remains below the 50-day ($30.01), indicating robust long-term and short-term support with some medium-term technical overhead. The immediate ceiling is at $30.01 while the floor is at $28.78, and the Ichimoku Kijun at $30.61 adds to the resistance. The 50-day and 200-day average alignment points to a bullish longer-term trend. Momentum indicators are mixed: the MACD (-0.32) shows strong downside pressure as a "Strong Sell" and the ADX at 8.27 signals weak directional strength. The RSI at 55.5 and Hull Moving Average at $29.24 both read "Buy", but Stochastic RSI (100), CCI (113.07), and Bull/Bear Power (3.08) all point to extreme overbought conditions. BBP above zero signals intraday buyer dominance, but these overbought signals warrant caution. The Awesome Oscillator is neutral, reflecting uncertainty in momentum. The daily loss to $29.33 was accompanied by intraday volatility of 8.32% and early downside gap, further emphasizing short-term caution.

Earlier, analysts noted that while Hims & Hers Health continued to display technical strength, emerging legal risks and heightened regulatory scrutiny could weigh on further gains. The latest press release inviting shareholders to lead a new class action lawsuit adds to these concerns, and traders should closely monitor the $27.29 downside level for any signs of a sustained technical breakdown.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.